Tensor Ventures is an investment firm operating in the advanced software sector.
Portfolio
3
companies
AppFactor
AppFactor builds an agentic orchestration platform for autonomous enterprise software maintenance.
Scalpel AI
Scalpel AI develops computer vision technology to track surgical instruments and streamline hospital logistics.
.png)
Antiverse
Antiverse develops AI-designed therapeutic antibodies for challenging disease targets using computational platforms and in-house laboratories.
Martin Drdul
founder & general partner
Martin serves as co-founder and general partner at Tensor Ventures. He also holds investor roles across several organisations, including GRAI, Cnuic Technologies, and AppFactor.
LinkedInOndřej Lipold
Partner
The seed round was led by Tensor Ventures to accelerate platform capabilities and go-to-market efforts.
"Enterprises have brilliant engineers spending the majority of their time maintaining the past instead of inventing what’s next. AppFactor changes that by turning software upkeep into an autonomous, closed-loop process. With the AppFactor Agentic Orchestration Platform handling maintenance, teams move much faster on the initiatives that grow the business."
"The success of any surgery depends not only on what happens inside the operating theatre but also on having a smooth-running operation behind the scenes. At Scalpel AI, we work with leading medical device companies and healthcare organisations to transform their logistical supply chain and reduce costs by millions of dollars. Together, we are making surgery safer for patients while paving the way for personalised surgery, which we believe is the future of healthcare."
The latest investment brings total equity financing to £7.2m and will support clinical progression of internal assets.
"A third of all FDA-approved drugs target GPCRs, yet, despite decades of research and billions of funding, only a few GPCR-targeting antibodies exist. Thanks to the support of our investors, we are one step closer to making GPCRs and other challenging targets druggable, bringing needed therapies to patients across the globe."
The financing was supported by new investors including InnoSpark alongside returning backers such as the Development Bank of Wales.
"This is the most comprehensive validation of our platform thus far. While identifying antibodies to GPCRs has traditionally been a complex and time-intensive process requiring expensive specialist technology and training, we have demonstrated that Antiverse’s drug discovery platform can achieve this in a fraction of the time and cost. GPCRs are commercially interesting targets associated with various indications, and these antibodies offer a path to first in vivo results and can potentially be our first assets. I would like to thank our investors, this funding will enable us to continue to develop these assets in-house with our academic collaborators."
The seed round was supported by a syndicate of investors including the Development Bank of Wales and the UKI2S Innovate Accelerator to fund platform development and laboratory expansion.
"Our investors recognise the potential of our AI-powered antibody drug discovery platform to provide a breakthrough in the industry. With our technology, it will be possible to develop drugs for difficult targets and ultimately reduce drug discovery timescales from years to weeks. In addition to platform development, the funding will enable us to invest in facilities and recruitment; we are grateful to our investors and Innovate UK for their continued support."
